Skip to main content


Table 8 Cost–utility ratios of triple therapy and triple therapy with zeaxanthin

From: Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis

Model TTZ vs TT TTZ vs. control cohort TT vs. control cohort
Incremental CUR Average CUR Average CUR
First-eye model $7470/QALY $22,958/QALY $28,142/QALY
Second-eye model $3395/QALY $15,926/QALY $23,850/QALY
Combined-eye model $5302/QALY $19,962/QALY $26.574/QALY